Dr. Garassino on Safety Protocols for Patients With Cancer in Italy During COVID-19

Video

In Partnership With:

Marina Chiara Garassino, MD, discusses key safety protocols that were initiated for patients with cancer in Italy during the COVID-19 pandemic.

Marina Chiara Garassino, MD, professor of medicine, Department of Medicine, Section of Hematology/Oncology, Knapp Center for Biomedical Discovery, The University of Chicago, discusses key safety protocols that were initiated for patients with cancer in Italy during the COVID-19 pandemic.

At the start of the COVID-19 pandemic, hospitals and cancer centers in Italy tried to delay all non-essential treatments for patients with cancer, including CT scans and MRIs, says Garassino.

After the first wave of COVID-19 infections, improved organization within cancer centers allowed normal care to be reinstated, Garassino explains. However, the inability for patients to bring someone with them to the clinic was a significant limitation of the safety protocols put in place, Garassino says. Additionally, patients were required to have a COVID-19 test before they were treated, change their masks frequently, and wash their hands frequently, Garassino says.

With those safety measures in place, as well as having a separate wing or area of the hospital reserved for patients with COVID-19, patients with cancer were generally protected against getting COVID-19 in the hospital, concludes Garassino.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD